No abstract

Itani reports receiving personal fees from Merck during the conduct of the study. Dr. Kelly reports receiving personal fees and nonfinancial support from Merck Canada during the conduct of the study. Dr. Nielsen reports receiving other assistance from Agilent outside of the submitted work. Dr. Spatz reports receiving personal fees and other assistance from Merck during the conduct of the study. Dr. Tsao reports receiving grants and personal fees from Merck during the conduct of the study. The remaining authors declare no conflict of interest.

Although there are rare cases of highly malignant anaplastic plasmacytomas, 3 most extramedullary plasmacytomas have a good prognosis; 4 our case shows that even tumours with anaplastic features may have a relatively indolent clinical course.